上海张江生物技术有限公司

Shanghai Zhangjiang Biotechnology is a Chinese biopharmaceutical company focused on the development of innovative recombinant protein therapeutics for cardiovascular and metabolic diseases. As a key subsidiary of CSPC Pharmaceutical Group, the company is recognized for developing Mingfule (rhTNK-tPA), a third-generation thrombolytic agent approved in China for acute myocardial infarction and currently in late-stage trials for ischemic stroke. The company operates advanced R&D and manufacturing facilities in the Zhangjiang Hi-Tech Park, specializing in genetic engineering and large-scale protein purification. Its pipeline also includes recombinant human GLP-1 for the treatment of type 2 diabetes. Shanghai Zhangjiang Biotechnology plays a critical role in CSPC's biologics strategy, providing high-value clinical solutions for life-threatening vascular conditions.